Patients with high SLC1A5 expression experienced poorer outcomes following endocrine therapy, while the co-expression of SLC1A5 and TALDO1 was significantly associated with a higher risk of recurrence and mortality in breast cancer patients receiving endocrine therapy [184]. Here, SLC1A5 is linked to breast carcinoma.